Agoracom Blog Home

Archive for the ‘Tetra Brio-Pharma Inc.’ Category

Pot stocks soar as legal weed seen surviving Trudeau tax $MCOA.us $TBP.ca

Posted by AGORACOM-JC at 8:54 AM on Thursday, November 17th, 2016
  • Canadian marijuana stocks surged after the head of the country’s biggest producer said his company could cope with taxes as high as 25 per cent, extending a rally that began in the summer with the prospect of legal recreational use.
  • Bruce Linton, chief executive officer of Canopy Growth Corp., says Prime Minister Justin Trudeau’s government will probably choose to control the distribution of legal recreational marijuana through government-run outlets such as liquor stores. A task force is due to report this month on how Canada can build a legal weed market.

“We can probably carry a tax burden of 25 per cent or so and end up in the consumer hands on a still cost-competitive basis, with a superior product,” Mr. Linton said Monday in an interview at Bloomberg’s Ottawa newsroom.

Canopy, based in Smith Falls, Ont., became the first marijuana producer to trade on a major North American stock exchange when it graduated to the Toronto Stock Exchange in July. It became the first publicly traded Canadian producer of the drug in 2014.

The company’s share price more than doubled this month, bringing its market value past $1.6-billion, on better-than-expected earnings and after U.S. elections widened the scope for legal marijuana. The stock was up as much as 33 per cent Wednesday, and was up 5.4 per cent to $14.17 as of 2:10 p.m. Toronto time.

Emerald Health Therapeutics Inc. jumped as much as 62 per cent intraday, and Aurora Cannabis Inc. climbed as much as 50 per cent.

“Anytime there’s more media attention to the sector it brings in more investors,” Jason Zandberg, an analyst covering marijuana producers at PI Financial Corp. in Vancouver, said by phone. “We found that there’s been a lot of interest from U.S. investors. They have a difficulty in investing in the sector given the weird framework that’s in the U.S. where it’s illegal at a federal level.”

Canopy already produces medical marijuana under an existing legal regime. Mr. Linton says the company, which operates out of a former chocolate factory, can shift production to serve the recreational market when Mr. Trudeau’s government makes that legal.

Part of the appeal of the legal variety will be its quality control, Mr. Linton says. “When it’s lawfully available from a reliable supply chain, which we know we can trust and believe in, there are a lot of people who might discontinue the use of say a glass of wine or a beer and try this.”

Canopy can also generate new formulations of medical marijuana to sell through pharmacies as legalization moves ahead, Linton said. Loblaw Cos., owner of the Shoppers Drug Mart pharmacy chain, said Wednesday its is engaging with the government to dispense marijuana from stores.

“There’s a lot of advantages for Canadian producers,” Mr. Zandberg said. Linton “pointed out some key points. I find there’s a lot of interesting aspects to this market that aren’t well known and he definitely highlighted a few that have caused a bit of excitement as well.”

Tetra Bio-Pharma Achieves DTC Eligibility in the United States $TBP.ca

Posted by AGORACOM-JC at 8:35 AM on Wednesday, November 16th, 2016

Tbp_large

  • Effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market
  • Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”.

OTTAWA, ONTARIO–(Nov. 16, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF) is pleased to announce that effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market.

Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors.

The Company’s common shares are listed for trading on the OTCPINK, a U.S. based securities trading system, under the symbol “GRPOF”. Tetra Bio-Pharma shares will continue to be traded on the Canadian Stock Exchange under its existing symbol “TBP”.

André Rancourt, Chief Executive Officer, commented, “We’re pleased to announce that our shares have become DTC eligible on the U.S. market and excited to bring our Company to the attention of the investment community in the U.S. We believe that GRPOF offers investors a unique opportunity to invest in a bio pharmaceutical cannabis company before entering clinical trials later this year.

In other company news

Website:

The Company is proud to announce that its website located at www.tetrabiopharma.com is now live. We encourage investors to sign up for news releases and notifications as more information is added to the website.

Industry Participation:

Dr. Guy Chamberland, Chief Scientific Officer and regulatory affairs, and Ryan Brown, co-founder and VP of Business Development, will be presenting at the World of Cannabis business summit in Las Vegas on November 16th 2016. Dr. Chamberland will be presenting as part of “the science of medical cannabis” program while Ryan Brown will be presenting at the “emerging brands investor pitch seminar” more info can be found at www.worldofcannabissummit.com.

Investor Relations:

The Company would like to inform investors that it has engaged Alpha Deal Group LLC, a New York based buy side analyst firm, to perform investor analysis for presentation to its investment network.

As released on November 9, 2016, via CFN (Cannabis Financial Network), the Company has engaged Cannabis Financial Network to increase its visibility in the United States retail investment market.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
Phone: (613) 421-8402

Ryan Brown
Co-founder and Director of Communications
Phone: (613) 421-8402

Andre Audet
Executive Chairman
Phone: (613) 421-8402

Canada could thrive from marijuana legalization in U.S. states $MCOA.us $TBP.ca

Posted by AGORACOM-JC at 3:52 PM on Thursday, November 10th, 2016
  • Voters in California, Massachusetts and Nevada approved on Tuesday the use of recreational cannabis, joining four other states and Washington, D.C., that have similar laws in place.
  • Florida, North Dakota and Arkansas approved medical marijuana, which would bring the total number of states with such a system to more than two dozen.
By ALEXANDRA POSADZKI The Canadian Press
Thu., Nov. 10, 2016

Canada’s marijuana industry could benefit after at least six states representing twice the population of Canada voted in favour of legalizing the drug, either recreationally or medically.

Voters in California, Massachusetts and Nevada approved on Tuesday the use of recreational cannabis, joining four other states and Washington, D.C., that have similar laws in place.

Florida, North Dakota and Arkansas approved medical marijuana, which would bring the total number of states with such a system to more than two dozen.

Shipping marijuana into the U.S., whether for medical or recreational purposes, is illegal. But the CEO of Privateer Holdings, a U.S.-based private equity firm that focuses on investing in the marijuana sector, says he expects Canadian producers will enter into partnerships and joint ventures with their neighbours to the south following the referendums.

“I think you’ll see Canadian companies jump at the opportunity to expand their operations and brands into the United States,” says Brendan Kennedy, whose firm owns Nanaimo, B.C.-based licensed producer Tilray.

That could mean everything from participating in the production process to providing consulting services or licensing intellectual property to U.S. producers, Kennedy says.

“There are huge opportunities for Canadian companies, because Canada has the most robust and tightly regulated medical cannabis framework in the world,” he says.

“Both governments and companies around the world are looking to Canada to provide leadership and expertise in this industry.”

People in Montana voted to expand its current medical marijuana regime. In Maine, voters appeared to be inching toward legalizing recreational use, but as of early Thursday, the results were still to close to call.

Presuming all eight states approve their various marijuana initiatives, that could inject $7.4 billion (U.S.) annually into the marijuana market by 2020, Arcview Market Research says. That would open the door to a recreational and medical marijuana market in the U.S. worth $21.2 billion by that same time, according to the research firm.

Alan Gertner, CEO of luxury marijuana brand Tokyo Smoke, says the legalization push means more opportunities for brand licensing deals. His company is already working with partners in Florida and Massachusetts, he said.

“Generally, more legal consumers means more opportunity to build and scale Canadian cannabis brands,” Gertner said in an email.

Canadian companies that build equipment and technology that help grow medical marijuana will also gain access to a larger market, he added.

Cam Battley, executive vice-president of Alberta-based licensed producer Aurora Cannabis Inc., says Canada is home to some of the largest commercial marijuana producers in the world.

Having a federally regulated medical marijuana regime — rather than a piecemeal, state-by-state system like the U.S. — has allowed Canadian marijuana companies to master large-scale, commercial production techniques, says Battley.

“We do have a lot of expertise, and we’ve learned, collectively as a sector, a lot of really important lessons about cultivation and consistent production,” says Battley.

“I think that does give us some advantages and would bode well for partnerships when the time is right.”

Khurram Malik, the cannabis lead at Jacob Capital Management, says the news could also help Canadian marijuana companies secure funding by making investors more comfortable with the sector.

“Most of the money raised up here is from the U.S.,” says Malik. “This legitimizes the concept of cannabis around the world, which is only a positive for the market up here.”

Source: https://www.thestar.com/news/canada/2016/11/10/canada-could-thrive-from-marijuana-legalization-in-us-states.html

Marijuana wins big on election night $MCOA.us $TBP.ca

Posted by AGORACOM-JC at 8:39 AM on Wednesday, November 9th, 2016


(Linda Davidson/The Washington Post)

  • On the medical side, voters in Florida, North Dakota and Arkansas have approved medical marijuana initiatives
  • separate measure in Montana that would loosen restrictions on an existing medical pot law was leading early Wednesday with only 30 percent of votes counted
  • Reformers were jubilant. “This represents a monumental victory for the marijuana reform movement,” said Ethan Nadelmann, executive director of the Drug Policy Alliance, in a statement. “With California’s leadership now, the end of marijuana prohibition nationally, and even internationally, is fast approaching.”

On the medical side, voters in Florida, North Dakota and Arkansas have approved medical marijuana initiatives. A separate measure in Montana that would loosen restrictions on an existing medical pot law was leading early Wednesday with only 30 percent of votes counted.

Reformers were jubilant. “This represents a monumental victory for the marijuana reform movement,” said Ethan Nadelmann, executive director of the Drug Policy Alliance, in a statement. “With California’s leadership now, the end of marijuana prohibition nationally, and even internationally, is fast approaching.”

How marijuana legalization in Washington, Colorado and Oregon is working out so far
Post)

California has long been seen as a bellwether by both supporters and opponents of marijuana reform. The state is home to about 12 percent of the U.S. population. Given the size of the state’s economy and the economic impact of the marijuana industry there, California’s adoption of legal marijuana could prompt federal authorities to rethink their decades-long prohibition on the use of marijuana.
In a recent interview with Bill Maher, President Obama said that passage of the legalization measures on Tuesday could make the current federal approach to the drug “untenable.”

Still, the likelihood of a Trump White House leaves a lot of uncertainty about the fate of marijuana measures in the next four years. Under Obama, federal authorities largely took a hands-off approach to state-level legalization efforts. But an incoming administration more skeptical of drug reform could easily reverse that approach.

“The prospect of Rudy Giuliani or Chris Christie as attorney general does not bode well,” the Drug Policy Alliance’s Nadelmann said in an interview. “There are various ways in which a hostile White House could trip things up.”

Still, Nadelmann pointed to the success of marijuana measures in the midst of an evident Republican wave as a sign that support for legalization now cuts deeply across party lines. And citing Trump’s often contradictory statements on marijuana and drug use in the past, Nadelmann added that “Donald Trump personally could probably go any which way on this.”

With today’s votes, legal marijuana is also making significant inroads in the Northeast. “Marijuana legalization has arrived on the East Coast,” said Tom Angell of the marijuana reform group Marijuana Majority in an email. “What Colorado and other states have already done is generating revenue, creating jobs and reducing crime, so it’s not surprising that voters in more places are eager to end prohibition.”

Opponents of legalization said they were disappointed by the outcomes. “We were outspent greatly in both California and Massachusetts, so this loss is disappointing, but not wholly unexpected,” said Kevin Sabet of the anti-legalization group Smart Approaches to Marijuana in a statement. “Despite having gained considerable ground in the last few weeks, the out-of-state interests determined to make money off of legalization put in too much money to overcome.”

Votes on medical marijuana in Florida and North Dakota were decisive. Florida’s Amendment 2 passed with 71 percent support, according to the Associated Press. In North Dakota, the AP reports that 64 percent of voters approving of the medical marijuana measure.

[One striking chart shows why pharma companies are fighting legal marijuana]

Two years ago, a medical marijuana measure in Florida earned 58 percent of the vote, just shy of the 60 percent threshold needed for passage. Then, as now, opposition to the measure was fueled by multimillion-dollar donations from Sheldon Adelson, the Las Vegas casino magnate and GOP donor. In 2014 Adelson spent $5.5 million to defeat the measure. This year he’s spent $1.5 million in Florida, and several million more to defeat recreational marijuana measures in other states.

“This is a major tipping point,” said Tom Angell of Florida’s vote. “With Florida’s decision, a majority of states in the U.S. now have laws allowing patients to find relief with medical marijuana, and these protections and programs are no longer concentrated in certain regions of the country like the West and Northeast.”

The victory in North Dakota is something of a surprise as no polling was done on the measure.

The Florida amendment has the potential to be one of the more permissive medical marijuana regimes in the nation. In addition to diseases like HIV, cancer and PTSD, the measure also allows doctors to recommend medical pot for “other debilitating medical conditions of the same kind or class as or comparable to those enumerated, and for which a physician believes that the medical use of marijuana would likely outweigh the potential health risks for a patient.” While the 2014 measure allowed doctors to prescribe marijuana for any illness they believed it would be useful for, the new measure requires they show the illness is severe — though the wording gives physicians considerable leeway in determining which conditions would meet those criteria.

The medical pot measure in North Dakota allows doctors to recommend the drug for a number of severe medical conditions.

With the passage of Amendment 2, Florida will become the first Southern state to enact a robust medical marijuana regime. Medical marijuana is already legal in 25 other states and the District.

Source: https://www.washingtonpost.com/news/wonk/wp/2016/11/08/medical-marijuana-sails-to-victory-in-florida/

Tetra Bio-Pharma Enters Into Medical Cannabis Supply Agreement With ACMPR Licensed Producer Aphria Inc. $TBP.ca

Posted by AGORACOM-JC at 8:36 AM on Thursday, November 3rd, 2016

Tbp_large

  • Signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR”) licensed producer Aphria Inc.
  • For the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001

OTTAWA, ONTARIO–(Nov. 3, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP“), is pleased to announce that it has signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR“) licensed producer Aphria Inc. (“Aphria“) (TSX VENTURE:APH)(OTCQB:APHQF) for the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe.

Aphria is a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations.Under this supply agreement with Aphria, PPP shall pursue the development of a prescription controlled inhalation drug product of medical marijuana and seek marketing approval across the world either directly or indirectly through partnerships or licensing agreements. Aphria will be the exclusive supplier of this API to PPP for the development and commercialisation of PP001.

PPP is granted an exclusive, non-transferrable, royalty free, licence to use the API in the development of PPP001. The agreement defines a purchase price during the clinical development and a volume rebate once a target volume is reached.

Both Canadian and USA prescription drug regulations impose rigorous quality systems for the manufacturing of both the API and finished drug product. These requirements include conformance to pharmaceutical Good Manufacturing Practice regulations (“GMP“) as well as demonstrating the ability of the manufacturer to ensure lot-to-lot consistency in the quality and safety of the prescription drug.

Dr. Guy Chamberland, M.Sc., Ph.D., Chief Scientific Officer and Regulatory Affairs, PhytoPain Pharma Inc., commented, “We are very pleased and excited to be working with Aphria in the development of PPP001. Developing prescription botanical based pharmaceuticals requires a high quality GMP system and well-established product specifications to ensure consistent efficacy and ultimately protect the safety of patients. Based on our assessment of Aphria, we are confident that their high quality GMP medical cannabis production facility and impressive quality assurance team will meet or exceed the expectations of both the Canadian and USA prescription drug authorities.”

“With this agreement in place, PPP is now in a solid position to submit its Clinical Trial Application (CTA) for its planned Phase I trial in healthy volunteers. The company is also on track for submitting its Pre-IND Information Package for its upcoming meeting the US FDA,” stated Dr. Chamberland.

“Aphria is excited and proud to be an integral part of advancing the scientific research being led by Dr. Chamberland and the team at Tetra Bio-Pharma. Using our proprietary and high quality medical cannabis blend supported by high calibre research is exactly what professional healthcare practitioners require to gain the confidence to prescribe medical cannabis as a pharmaceutical,” said Vic Neufeld, Chief Executive Officer, Aphria Inc.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Neither the TSX Venture Exchange (the “Exchange”) nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer

Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications

Tetra Bio-Pharma Inc.
André Audet
Executive Chairman
(613) 421-8402

Aphria Inc.
Vic Neufeld
1-844-427-4742

Tetra Bio-Pharma Announces Outcome of its Meeting with its Scientific and Clinical Advisory Board $TBP.ca

Posted by AGORACOM-JC at 1:20 PM on Wednesday, November 2nd, 2016

Tbp_large

  • Held its Scientific and Clinical Advisory Board (“CAB”) meeting on October 29th
  • CAB reviewed the development program of PPP’s inhalation cannabis product PPP001
  • Medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe

OTTAWA, ONTARIO–(Nov. 2, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP“), is pleased to announce that it held its Scientific and Clinical Advisory Board (“CAB“) meeting on October 29th. The CAB reviewed the development program of PPP’s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe.

The Board, which is comprised of experts in clinical research, pain management as well as cancer, and neurological product drug development (ref: news release August 26, 2016), met to review and discuss the development program to date, the study design of the Phase I trial and the overall clinical development plan of PPP001. This included the exclusion and inclusion criteria of the proposed Phase I trial, the Phase 1a and 1b dosing scheme, and the pharmacokinetic and pharmacodynamic assessments. The CAB also examined the clinical rationale for the selection of the delta-9-tetrahydrocannibinol (THC) and Cannabidiol (CBD) dose levels for use in PPP001.

The CAB also reviewed the salient elements of future PPP’s Phase II and III clinical trials for the development of PPP001 in various medical conditions, including the use of medical marijuana as a second or third line therapy for cancer and HIV patients with uncontrolled pain. The CAB reports directly to the Board of Directors of the Company and will be submitting a report on the outcome of the CAB meeting in the near future.

Currently, there is only limited safety or efficacy information, if any, derived from well-controlled clinical trials available to physicians to adequately assess the benefits and risks of prescribing medical marijuana. Dr. Luc Vachon, President of the CAB commented: ²the members of the CAB are very pleased and excited to be participating in a full pharmaceutical approach on the development of medical marijuana as a prescription drug. The members expressed that the clinical development plan used by PPP – supported by a formal regulatory path – will help generate the type of clinical information required by physicians.²

“This team of scientific and clinical experts provided us with excellent guidance on the development program. We are pleased to recommend to the Board of Directors that PPP is ready to submit the Clinical Trial Application (CTA) for the conduct of its Phase I trial in healthy human volunteers,” stated Dr. Chamberland, Chief Scientific Officer and Regulatory Affairs.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer
(613) 421-8402

Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
(613) 421-8402

Tetra Bio-Pharma Inc.
André Audet
Executive Chairman
(613) 421-8402

 

Tetra Bio-Pharma Announces Acquisition of Intellectual Property for the Development of Natural Health Products Through Its Agro-Tek Subsidiary $TBP.ca

Posted by AGORACOM-JC at 8:35 AM on Wednesday, October 26th, 2016

Tbp_large

  • Announced that it has acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa
  • Recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content

OTTAWA, ONTARIO–(Oct. 26, 2016) – Tetra Bio-Pharma Inc. (“Tetra Bio” or the “Company“) (CSE:TBP)(CSE:TBP.CN), through its subsidiary, Agro-Tek Inc. (“AGTK“), is pleased to announce that it has acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa.

The recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content. According to the United States Food and Drug Administration (“FDA“), “FDA is not aware of any evidence that would call into question its current conclusion that cannabidiol products are excluded from the dietary supplement definition under section 201(f)(3)(B)(ii) of the Federal Food, Drug, & Cosmetics Act.”

Mr. André Rancourt, the Company’s CEO commented, “CBD or THC containing dietary supplements are currently not allowed on the USA market. However, the goal of the McGill University partnership is the development of extracts of the plant Cannabis sativa, including THC and CBD-free for the development of dietary supplements.” AGTK intends on manufacturing and commercializing supplements, food-type products and, natural health products that are compliant with Canadian and USA federal regulations. Mr. Rancourt added, “This commercial strategy involves the expertise of two of the Company’s subsidiaries, AGTK and MMP, and is in line with the Company’s vision to make AGTK and MMP leaders in the development of Cannabis sativa, derived products for the consumer market, and for the commercialization of natural supplements derived from Cannabis sativa.”

The assets acquired include proprietary formulations that have obtained marketing approval from Health Canada. The line consists of:

1. Glucose Aid; NPN 80058089

2. Kava Kava; NPN 80061986

3. Stress Ado; NPN 80065911

4. Toux Ado (Cough Ado); NPN 80065923

5. Toux enfant (Cough Children); NPN 80065928

6. Water Relax; NPN 80065948 (beverage supplement)

7. Water Cough; NPN 80066086 (beverage supplement)

8. Sleep Pro; NPN 80066679

9. Instant Relief; NPN 80066682 (topical gel for local pain relief).

The acquisition of these formulations and their proprietary ingredients will provide PhytoPain Pharma Inc. with an inventory of compounds and elements that will be used as secondary ingredients or catalysts in the formulation of our pharmaceutical grade products.

In consideration for the acquisition of the assets, the Company has issued 1,800,000 common shares to arms’ length individuals. The shares issued will be subject to a four-month hold period.

According to Mr. Rancourt, these products will allow AGTK to begin generating revenues. This is the first set of products for AGTK’s portfolio. The company will be seeking to acquire additional product lines for distribution in North America. AGTK is engaged in negotiations to acquire national distributors to expand brand identity and facilitate distribution across North America

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer

Ryan Brown
VP Business Development and Communications

Andre Audet
Executive Chairman
(613) 421-8402
Investors@tetrabiopharma.com

Tetra Bio-Pharma Inc. Is Increasing Its $750,000 Non-Brokered Private Placement $TBP.ca

Posted by AGORACOM-JC at 4:33 PM on Monday, October 24th, 2016

Tbp_large

  • Increasing its $750,000 non-brokered private placement (ref.: news release of October 20, 2016) to $1,000,000 for up to 6,666,667 units at a price of $0.15 per unit
  • Each unit will be consisting of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.20 for a period of 12 months following the closing date

OTTAWA, ONTARIO–(Oct. 24, 2016) – Tetra Bio-Pharma Inc. (“Tetra Bio” or “the Company”) (CSE:TBP)(CSE:TBP.UN) is increasing its $750,000 non-brokered private placement (ref.: news release of October 20, 2016) to $1,000,000 for up to 6,666,667 units at a price of $0.15 per unit. Each unit will be consisting of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.20 for a period of 12 months following the closing date.

The private placement is expected to close no later than November 30, 2016.

The securities issued pursuant to the private placement will be subject to a four-month hold period from the closing date. The Company may pay a commission in connection with the private placement, subject to compliance with the policies of the Exchange. Completion of the private placement and the payment of any commissions remain subject to the receipt of all necessary regulatory approvals, including the approval of the Exchange.

The proceeds of the private placement will be used to initiate clinical trials.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Andre Rancourt
Chief Executive Officer

Ryan Brown
VP Business Development and Communications

André Audet
Executive Chairman
Investors@tetrabiopharma.com
(613) 421-8402

Tetra Bio-Pharma Inc. Announces a $750,000 Non-Brokered Private Placement & Granting of Options $TBP.ca

Posted by AGORACOM-JC at 8:37 AM on Thursday, October 20th, 2016

Tbp_large

  • Non-brokered private placement of up to 5,000,000 units at a price of $0.15 per unit for aggregate gross proceeds of up to $750,000
  • Each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.20 for a period of 12 months following the closing date.

OTTAWA, ONTARIO–(Oct. 20, 2016) – Tetra Bio-Pharma Inc. (“Tetra Bio” or “the Company”) (CSE:TBP)(CSE:TBP.CN) is conducting a non-brokered private placement of up to 5,000,000 units at a price of $0.15 per unit for aggregate gross proceeds of up to $750,000. Each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.20 for a period of 12 months following the closing date.

The private placement is expected to close no later than November 30, 2016.

The securities issued pursuant to the private placement will be subject to a four-month hold period from the closing date. The Company may pay a commission in connection with the private placement, subject to compliance with the policies of the Exchange. Completion of the private placement and the payment of any commissions remain subject to the receipt of all necessary regulatory approvals, including the approval of the Exchange.

The proceeds of the private placement will be used to initiate clinical trials.

In other News:

The Company has received $341,783 in exercised warrants from September to October 2016.

The Company also announces that in accordance with the Company’s stock option plan and subject to the approval of the Canadian Securities Exchange, the Board of Directors granted an aggregate of 800,000 incentive stock options (“options”) to directors of the Company. Each option, vesting immediately upon grant, entitles the holder thereof to purchase one common share in the capital of the Company at a price of $0.18 per share until October 19, 2021. The options and any common shares issued upon exercise thereof will be subject to a four month resale restriction from the date of grant.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 421-8402

Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
(613) 421-8402

Tetra Bio-Pharma Inc.
Andre Audet
Executive Chairman
(613) 421-8402
Investors@tetrabiopharma.com

Tetra Bio-Pharma Announces Awarding of NSERC Engage Grant Partnership to Grow Pros MMP and McGill University $TBP.ca

Posted by AGORACOM-JC at 8:31 AM on Wednesday, October 19th, 2016

Tbp_large

  • Announce that the National Sciences and Engineering Research Council of Canada (NSERC) has awarded an NSERC Engage Grant partnership to MMP and Dr. Stan Kubow of McGill University
  • As part of MMP’s mission to diversify and offer new products to consumers, with the award of the NSERC Engage partnership grant, MMP will establish a first research collaboration with McGill University and plans to invest in this program both financially and with in-kind contributions

OTTAWA, ONTARIO–(Oct. 19, 2016) – Grow Pros MMP Inc. (MMP), a subsidiary of Tetra Bio-Pharma Inc. (“TetraBio” or the “Company” or “TBP“) (CSE:TBP) is pleased to announce that the National Sciences and Engineering Research Council of Canada (NSERC) has awarded an NSERC Engage Grant partnership to MMP and Dr. Stan Kubow of McGill University.

As part of MMP’s mission to diversify and offer new products to consumers, with the award of the NSERC Engage partnership grant, MMP will establish a first research collaboration with McGill University and plans to invest in this program both financially and with in-kind contributions to pursue its research and development objectives and become a world leader in the development and commercialization of Cannabis-based products.

“The partnership with McGill University is in line with MMP’s vision to expand commercial operations and prepare to launch Cannabis sativa-derived supplement/retail or drug products for the North American market. This project will allow the development of intellectual property to protect future products that would be commercialized by TBP,” commented Ryan Brown.

“The proposed collaboration between Dr S. Kubow, Associate Professor, McGill University, relates to MMP’s need to develop an extraction process and to develop products using specific fractions of the plant Cannabis sativa. Fractions with the highest dermal and oral absorption will subsequently be characterized to further understand the pharmacology of these extracts,” commented Dr. Randy Ringuette, Ph.D. Medical Researcher, MMP Inc.

Dr. Stan Kubow stated, “We are excited by the collaboration with MMP that will allow us to utilize systematic state-of-the-art research methodologies to identify bioactives from Cannabis sativa for the development of science-based consumer products.”

According to Mr. A. Rancourt CEO of TBP, “We are very pleased by the decision of NSERC to award this partnership grant. This has implications for both MMP and AgroTek.” He added, “This is in line with TBP’s vision to make MMP a leader in the development of Cannabis sativa derived products for the consumer market and for the commercialization of natural supplements derived from Cannabis sativa by AgroTek.”

About Dr. Stan Kubow

Dr. S. Kubow, Ph.D. is an Associate Professor at the School of Dietetics and Human Nutrition, McGill University. His research interests include the impact of nutritional interventions on a variety of disease outcomes and metabolic disorders using technologically modified food extracts and isolates with enhanced bioactivity including phytochemical extracts, whey and soy proteins and probiotics. These studies have been focused upon oxidative stress, inflammatory indices, lipoprotein, fatty acid and glucose metabolism as related to cell signaling pathways and disease pathogenesis.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 421-8402
Investors@tetrabiopharma.com